<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33728549</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinson's and Huntington's diseases.</ArticleTitle><Pagination><StartPage>4997</StartPage><EndPage>5006</EndPage><MedlinePgn>4997-5006</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-021-05169-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The study aims at investigating psychometric properties of the Edinburgh cognitive and behavioural ALS screen (ECAS) in Parkinson's (PD) and Huntington's (HD) diseases. The sensitivity and specificity of the ECAS in highlighting HD and PD cognitive-behavioural features and in differentiating between these two populations and from healthy controls (HC) were evaluated. Moreover, correlations between the ECAS and traditional cognitive measures, together with core clinical features, were analysed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Seventy-three PD patients, 38 HD patients, and 49 education-matched healthy participants were enrolled. Participants were administered the ECAS, together with other cognitive screening tools and psychological questionnaires. Patients' behavioural assessment was also carried out with carers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The ECAS distinguished between HD patients and HC and between the two clinical syndromes with high sensitivity and specificity. Even if the diagnostic accuracy of the ECAS in distinguishing between PD and HC was low, the PD cognitive phenotype was very well described by the ECAS performances. Convergent validity of the ECAS against other traditional cognitive screening was observed, as well as correlations with psychological aspects and typical clinical features, especially for the HD group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ECAS represents a rapid and feasible tool, useful also in other neurodegenerative disorders affecting verbal-motor abilities than the amyotrophic lateral sclerosis such as PD and HD. Clinical applications in these neurodegenerative conditions require further investigations and, probably, some adaptations of the original test.</AbstractText><CopyrightInformation>&#xa9; 2021. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Carelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Solca</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migliore</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo Della Sofferenza Research Hospital, San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brugnera</LastName><ForeName>Agostino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Human and Social Sciences, University of Bergamo, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagini</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ASST Santi Paolo e Carlo, Neurology Clinic III, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maffi</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo Della Sofferenza Research Hospital, San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccarelli</LastName><ForeName>Consuelo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Italian League for Research on Huntington Disease (LIRH) Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquini</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sassone</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroscience San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squitieri</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo Della Sofferenza Research Hospital, San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciammola</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. a.ciammola@auxologico.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4398-2051</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. b.poletti@auxologico.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognitive assessment</Keyword><Keyword MajorTopicYN="N">ECAS</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Movement disorders</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Psychological symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>7</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33728549</ArticleId><ArticleId IdType="doi">10.1007/s10072-021-05169-3</ArticleId><ArticleId IdType="pii">10.1007/s10072-021-05169-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Galtier I, Nieto A, Lorenzo JN, Barroso J (2016) Mild cognitive impairment in Parkinson&#x2019;s disease: diagnosis and progression to dementia. J Clin Exp Neuropsychol 38:40&#x2013;50. https://doi.org/10.1080/13803395.2015.1087465</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13803395.2015.1087465</ArticleId><ArticleId IdType="pubmed">26602176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson RA, Yarnall AJ, Duncan GW et al (2014) Severity of mild cognitive impairment in early Parkinson&#x2019;s disease contributes to poorer quality of life. Parkinsonism Relat Disord 20:1071&#x2013;1075. https://doi.org/10.1016/j.parkreldis.2014.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2014.07.004</ArticleId><ArticleId IdType="pubmed">25074728</ArticleId><ArticleId IdType="pmc">4194347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart EP, Dumas EM, Giltay EJ et al (2013) Cognition in Huntington&#x2019;s disease in manifest, premanifest and converting gene carriers over ten years. J Huntingtons Dis 2:137&#x2013;147. https://doi.org/10.3233/JHD-130059</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-130059</ArticleId><ArticleId IdType="pubmed">25063511</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs M, Hart EP, Roos RAC (2018) Cognitive performance and apathy predict unemployment in Huntington&#x2019;s disease mutation carriers. J Neuropsychiatr Clin Neurosci 30:188&#x2013;193. https://doi.org/10.1176/appi.neuropsych.17070144</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.neuropsych.17070144</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Goldman JG, Tr&#xf6;ster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson&#x2019;s disease: movement disorder society task force guidelines. Mov Disord 27:349&#x2013;356. https://doi.org/10.1002/mds.24893</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.24893</ArticleId><ArticleId IdType="pubmed">22275317</ArticleId><ArticleId IdType="pmc">3641655</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E et al (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Front Degener 15:9&#x2013;14. https://doi.org/10.3109/21678421.2013.805784</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L et al (2016) The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotroph Lateral Scler Front Degener 17:489&#x2013;498. https://doi.org/10.1080/21678421.2016.1183679</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1183679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremolizzo L, Lizio A, Santangelo G et al (2020) ALS cognitive behavioral screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurol Sci 41:835&#x2013;841. https://doi.org/10.1007/s10072-019-04154-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04154-1</ArticleId><ArticleId IdType="pubmed">31807998</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456&#x2013;2477. https://doi.org/10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId><ArticleId IdType="pmc">3170532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kourtesis P, Christidi F, Margioti E et al (2019) The Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS): sensitivity in differentiating between ALS and Alzheimer&#x2019;s disease in a Greek population. Amyotroph Lateral Scler Front Degener. https://doi.org/10.1080/21678421.2019.1655059</Citation></Reference><Reference><Citation>Foley JA, Niven EH, Paget A et al (2018) Sensitivity and specificity of the ECAS in Parkinson&#x2019;s disease and progressive supranuclear palsy. https://doi.org/10.1155/2018/2426012</Citation></Reference><Reference><Citation>Kieburtz K, Penney JB, Corno P et al (1996) Unified Huntington&#x2019;s disease rating scale: reliability and consistency. Mov Disord 11:136&#x2013;142. https://doi.org/10.1002/mds.870110204</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.870110204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S (1987) Members of the UPDRS development committee. Unified Parkinson&#x2019;s disease rating scale. Recent Dev Park Dis 2:293&#x2013;304</Citation></Reference><Reference><Citation>Alberici A, Geroldi C, Cotelli M et al (2007) The frontal behavioural inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer&#x2019;s disease. Neurol Sci 28:80&#x2013;86. https://doi.org/10.1007/s10072-007-0791-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-007-0791-3</ArticleId><ArticleId IdType="pubmed">17464470</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti S, Bonazzi S, Laiacona M et al (2015) Montreal cognitive assessment (MoCA)-Italian version: regression based norms and equivalent scores. Neurol Sci 36:209&#x2013;214</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-014-1921-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafin M, Surian L (2004) Il Test degli Occhi: uno strumento per valutare la &#x201c;teoria della mente.&#x201d;. G Ital Psicol 31:839&#x2013;862. https://doi.org/10.1421/18849</Citation><ArticleIdList><ArticleId IdType="doi">10.1421/18849</ArticleId></ArticleIdList></Reference><Reference><Citation>Santangelo G, Raimo S, Siciliano M et al (2017) Assessment of apathy independent of physical disability: validation of the dimensional apathy scale in Italian healthy sample. Neurol Sci 38:303&#x2013;309. https://doi.org/10.1007/s10072-016-2766-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-016-2766-8</ArticleId><ArticleId IdType="pubmed">27844173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrabissi L, Santinello M (1989) Inventario per l&#x2019;ansia di &#xab;Stato&#xbb; e di &#xab;Tratto&#xbb;: nuova versione italiana dello STAI Forma Y: Manuale</Citation></Reference><Reference><Citation>Spielberger CD (2010) State-trait anxiety inventory. In: The Corsini Encyclopedia of Psychology. Wiley, Hoboken, pp 3&#x2013;4</Citation></Reference><Reference><Citation>Centomo C, Sanavio E (1992) Padua inventory e Beck depression inventory: Indagine su studenti di scuola media superiore. Manuscr not Publ</Citation></Reference><Reference><Citation>Swets JA (1988) Measuring the accuracy of diagnostic systems. Science (80- ) 240:1285&#x2013;1293</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3287615</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289&#x2013;300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J (2013) Statistical power analysis for the behavioral sciences. Routledge</Citation></Reference><Reference><Citation>Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC (2014) The cognitive burden in Huntington&#x2019;s disease: pathology, phenotype, and mechanisms of compensation. Mov Disord 29:673&#x2013;683. https://doi.org/10.1002/mds.25864</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25864</ArticleId><ArticleId IdType="pubmed">24757115</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L et al (2018) Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh cognitive and behavioral ALS screen (ECAS). Amyotroph Lateral Scler Front Degener 19:387&#x2013;395. https://doi.org/10.1080/21678421.2018.1473443</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1473443</ArticleId></ArticleIdList></Reference><Reference><Citation>Enrici I, Adenzato M, Ardito RB et al (2015) Emotion processing in Parkinson&#x2019;s disease: a three-level study on recognition, representation, and regulation. https://doi.org/10.1371/journal.pone.0131470</Citation></Reference><Reference><Citation>Tsuruya N, Kobayakawa M, Kawamura M (2011) Is &#x201c;reading mind in the eyes&#x201d; impaired in Parkinson&#x2019;s disease? Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2010.09.001</Citation></Reference><Reference><Citation>Carelli L, Solca F, Faini A et al (2018) The complex interplay between depression/anxiety and executive functioning: insights from the ECAS in a large ALS population. Front Psychol 9:1&#x2013;8. https://doi.org/10.3389/fpsyg.2018.00450</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2018.00450</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano M, Trojano L, Trojsi F et al (2017) Edinburgh cognitive and behavioural ALS screen (ECAS)-Italian version: regression based norms and equivalent scores. Neurol Sci 38:1059&#x2013;1068. https://doi.org/10.1007/s10072-017-2919-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-2919-4</ArticleId><ArticleId IdType="pubmed">28332040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33&#x2013;39. https://doi.org/10.1001/archneur.56.1.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.1.33</ArticleId><ArticleId IdType="pubmed">9923759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>